BAY 1158061 (anti-PRLR) is a potent monoclonal antibody, targeting prolactin (PRL) receptor. It is considered a good candidate for further development in endometriosis or other PRL-mediated disease conditions.Purity>95%
BAY 1158061 (anti-PRLR) is a potent monoclonal antibody, targeting prolactin (PRL) receptor. It is considered a good candidate for further development in endometriosis or other PRL-mediated disease conditions.Purity>95%
BAY 1158061 (anti-PRLR) is a potent monoclonal antibody, targeting prolactin (PRL) receptor. It is considered a good candidate for further development in endometriosis or other PRL-mediated disease conditions.Purity>95%
BAY 1158061 (anti-PRLR) is a potent monoclonal antibody, targeting prolactin (PRL) receptor. It is considered a good candidate for further development in endometriosis or other PRL-mediated disease conditions.Purity>95%
BAY 1158061 (anti-PRLR) is a potent monoclonal antibody, targeting prolactin (PRL) receptor. It is considered a good candidate for further development in endometriosis or other PRL-mediated disease conditions.Purity>95%
BAY 1158061 (anti-PRLR) is a potent monoclonal antibody, targeting prolactin (PRL) receptor. It is considered a good candidate for further development in endometriosis or other PRL-mediated disease conditions.Purity>95%
Belimumab (anti-TNFSF13B) is a human IgG1λ monoclonal antibody that inhibits B-cell activating factor (BAFF). Belimumab (anti-TNFSF13B) can be used for systemic lupus erythematosus (SLE) research.Purity>95% (SDS-PAGE&SEC)Endotoxin Level<
Belimumab (anti-TNFSF13B) is a human IgG1λ monoclonal antibody that inhibits B-cell activating factor (BAFF). Belimumab (anti-TNFSF13B) can be used for systemic lupus erythematosus (SLE) research.Purity>95% (SDS-PAGE&SEC)Endotoxin Level<
Belimumab (anti-TNFSF13B) is a human IgG1λ monoclonal antibody that inhibits B-cell activating factor (BAFF). Belimumab (anti-TNFSF13B) can be used for systemic lupus erythematosus (SLE) research.Purity>95% (SDS-PAGE&SEC)Endotoxin Level<
Belimumab (anti-TNFSF13B) is a human IgG1λ monoclonal antibody that inhibits B-cell activating factor (BAFF). Belimumab (anti-TNFSF13B) can be used for systemic lupus erythematosus (SLE) research.Purity>95% (SDS-PAGE&SEC)Endotoxin Level<
Belimumab (anti-TNFSF13B) is a human IgG1λ monoclonal antibody that inhibits B-cell activating factor (BAFF). Belimumab (anti-TNFSF13B) can be used for systemic lupus erythematosus (SLE) research.Purity>95% (SDS-PAGE&SEC)Endotoxin Level<
Belimumab (anti-TNFSF13B) is a human IgG1λ monoclonal antibody that inhibits B-cell activating factor (BAFF). Belimumab (anti-TNFSF13B) can be used for systemic lupus erythematosus (SLE) research.Purity>95% (SDS-PAGE&SEC)Endotoxin Level<
Bersanlimab (anti-ICAM1) is a fully human monoclonal antibody that targets intercellular adhesion molecule-1 (ICAM-1 or CD54). Bersanlimab (anti-ICAM1) has anticancer effects.Purity>95% (SDS-PAGE&SEC)Endotoxin Level< 1.0EU/mg
Bersanlimab (anti-ICAM1) is a fully human monoclonal antibody that targets intercellular adhesion molecule-1 (ICAM-1 or CD54). Bersanlimab (anti-ICAM1) has anticancer effects.Purity>95% (SDS-PAGE&SEC)Endotoxin Level< 1.0EU/mg
Bersanlimab (anti-ICAM1) is a fully human monoclonal antibody that targets intercellular adhesion molecule-1 (ICAM-1 or CD54). Bersanlimab (anti-ICAM1) has anticancer effects.Purity>95% (SDS-PAGE&SEC)Endotoxin Level< 1.0EU/mg
Bersanlimab (anti-ICAM1) is a fully human monoclonal antibody that targets intercellular adhesion molecule-1 (ICAM-1 or CD54). Bersanlimab (anti-ICAM1) has anticancer effects.Purity>95% (SDS-PAGE&SEC)Endotoxin Level< 1.0EU/mg
Bersanlimab (anti-ICAM1) is a fully human monoclonal antibody that targets intercellular adhesion molecule-1 (ICAM-1 or CD54). Bersanlimab (anti-ICAM1) has anticancer effects.Purity>95% (SDS-PAGE&SEC)Endotoxin Level< 1.0EU/mg
Bersanlimab (anti-ICAM1) is a fully human monoclonal antibody that targets intercellular adhesion molecule-1 (ICAM-1 or CD54). Bersanlimab (anti-ICAM1) has anticancer effects.Purity>95% (SDS-PAGE&SEC)Endotoxin Level< 1.0EU/mg
Bersanlimab (anti-ICAM1) is a fully human monoclonal antibody that targets intercellular adhesion molecule-1 (ICAM-1 or CD54). Bersanlimab (anti-ICAM1) has anticancer effects.Purity>95% (SDS-PAGE&SEC)Endotoxin Level< 1.0EU/mg
Bersanlimab (anti-ICAM1) is a fully human monoclonal antibody that targets intercellular adhesion molecule-1 (ICAM-1 or CD54). Bersanlimab (anti-ICAM1) has anticancer effects.Purity>95% (SDS-PAGE&SEC)Endotoxin Level< 1.0EU/mg
Bexmarilimab (anti-STAB1) is a potent humanized anti-CLEVER-1 IgG4-antibody with an IC50 value of 4.51 nM. Bexmarilimab (anti-STAB1) is capable of inducing a phenotypic M2 to M1 immune switch of tumor-associated macrophages. Bexmarilimab
Bexmarilimab (anti-STAB1) is a potent humanized anti-CLEVER-1 IgG4-antibody with an IC50 value of 4.51 nM. Bexmarilimab (anti-STAB1) is capable of inducing a phenotypic M2 to M1 immune switch of tumor-associated macrophages. Bexmarilimab
Bexmarilimab (anti-STAB1) is a potent humanized anti-CLEVER-1 IgG4-antibody with an IC50 value of 4.51 nM. Bexmarilimab (anti-STAB1) is capable of inducing a phenotypic M2 to M1 immune switch of tumor-associated macrophages. Bexmarilimab
Bexmarilimab (anti-STAB1) is a potent humanized anti-CLEVER-1 IgG4-antibody with an IC50 value of 4.51 nM. Bexmarilimab (anti-STAB1) is capable of inducing a phenotypic M2 to M1 immune switch of tumor-associated macrophages. Bexmarilimab